Neoadjuvant therapy for gastrointestinal stromal tumor (GIST): Racing against resistance

Annals of Surgical Oncology

Volumn 14, Issue 4, 2007, Pages 1247-1248

  Gold, Jason S ^a   DeMatteo, Ronald P ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; STEM CELL FACTOR;

CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER RESISTANCE; CANCER SIZE; EARLY DIAGNOSIS; EDITORIAL; EXON; GASTROINTESTINAL STROMAL TUMOR; GENE DELETION; GENE MUTATION; HUMAN; LIVER BIOPSY; LIVER RESECTION; MUTATIONAL ANALYSIS; PATIENT ASSESSMENT; SPLENECTOMY; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; GASTROINTESTINAL STROMAL TUMORS; HUMANS; NEOADJUVANT THERAPY; PIPERAZINES; PYRIMIDINES; STOMACH NEOPLASMS;

EID: 34047237608     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-006-9291-6     Document Type: Editorial

References (3)

1. Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, Eisenberg BL, von Mehren M, Fletcher CD, Sandau K, McDougall K, Ou WB, Chen CJ, Fletcher JA. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006; epub Sep 5.
2. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, Issels R, van Oosterom A, Hogendoorn PC, Van Glabbeke M, Bertulli R, Judson I. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364:1127-34.
3. Gold JS, DeMatteo RP. Combined surgical and molecular therapy: the gastrointestinal stromal tumor model. Ann Surg 2006; 244:176-84.